ASCEND BY NTHRYS
Research Abroad Products

Genetics Project Topics

Browse all focused areas across all project categories under this field.

Showing 1741–1752 of 2020 project topics
Stevens-Johnson Syndrome HLA Risk Allele Testing
Implementing HLA-B*15:02 and HLA-A*31:01 testing before carbamazepine initiation in Asian populations for preventing severe cutaneous adverse reactions.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Drug-Induced Agranulocytosis Genetic Markers
Identifying HLA and non-HLA genetic markers predisposing to clozapine, carbimazole, and other drug-induced agranulocytosis events.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Statin Myopathy SLCO1B1 Genotyping
Implementing SLCO1B1 c.521T>C genotyping for predicting simvastatin-induced myopathy risk for personalizing statin type and dose selection.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Methotrexate Toxicity Genetic Predictors
Identifying MTHFR, ABCC2, and other genetic variants predicting methotrexate toxicity in RA and cancer patients for personalized monitoring.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Warfarin CYP2C9 and VKORC1 Dosing Algorithm Platform
A cloud-based pharmacogenomic decision support system that integrates CYP2C9 and VKORC1 genotyping data to generate personalized warfarin dosing recommendations for anticoagulation therapy. This platform reduces adverse bleeding events by 40% and generates revenue through per-test licensing, EHR integration fees, and clinical trial partnerships.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Thiopurine Methyltransferase Deficiency Screening SaaS
A subscription-based diagnostic platform that identifies TPMT variants before thiopurine immunosuppressant administration to prevent myelosuppression and severe toxicity. The service captures recurring B2B revenue from hospital networks, insurance companies, and specialty pharmacies through annual contracts and volume-based pricing models.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Abacavir HLA-B5701 Pre-Treatment Genetic Testing Kit
A rapid, point-of-care genetic test kit designed for HIV clinics and treatment centers to screen HLA-B5701 status prior to abacavir antiretroviral therapy initiation. Revenue streams include direct kit sales to healthcare facilities, reimbursement from insurance providers, and partnership licensing with diagnostic laboratories worldwide.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Clopidogrel CYP2C19 Loss-of-Function Genetic Biomarker Platform
An integrated genomic testing and electronic clinical decision tool that identifies CYP2C19 poor metabolizers to recommend alternative antiplatelet therapy and prevent stent thrombosis. The commercial model combines per-test fees, cardiology clinic licensing agreements, and outcomes-based contracts with hospital systems and interventional departments.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Phenytoin and Carbamazepine Epilepsy Genetic Toxicity Predictor
A machine learning-driven software platform that combines HLA and CYP2C9 genotyping with phenotype data to predict severe cutaneous adverse reactions before antiepileptic drug administration. This technology monetizes through neurology practice subscriptions, pharma research partnerships, and institutional licensing across epilepsy treatment networks and specialized neurology clinics.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Irinotecan UGT1A1 Pharmacogenetic Dosing Optimization Service
A clinical laboratory and software service that genotypes UGT1A1 variants in cancer patients to optimize irinotecan dosing and minimize severe neutropenia and diarrhea toxicity. The enterprise revenue model includes per-patient test fees, oncology center partnerships, pharmaceutical company collaborations for clinical trials, and regional laboratory network expansions.
Genetic Pharmacovigilance and Toxicogenomics Click to view more details →
Keratoconus Genetic Risk Factor Identification
Investigating COL5A1, FNDC3B, and GWAS-identified variants contributing to keratoconus susceptibility for genetic risk stratification.
Genetic Basis of Corneal and Anterior Segment Disorders Click to view more details →
Meesmann Corneal Dystrophy KRT3 KRT12 Testing
Identifying KRT3 and KRT12 variants causing Meesmann corneal dystrophy for molecular diagnosis in families with juvenile epithelial corneal dystrophy.
Genetic Basis of Corneal and Anterior Segment Disorders Click to view more details →